These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38445541)

  • 21. Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
    Lund LH; Lam CSP; Pizzato PE; Gabrielsen A; Michaëlsson E; Nelander K; Ericsson H; Holden J; Folkvaljon F; Mattsson A; Collén A; Aurell M; Whatling C; Baldus S; Drelich G; Goudev A; Merkely B; Bergh N; Shah SJ
    Eur J Heart Fail; 2023 Sep; 25(9):1696-1707. PubMed ID: 37470101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants.
    Zhang Y; Bush M; Yazdani P; Zhan J; Wen B; Bainbridge V; Wynne BR; Joshi S; Lataillade M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01151. PubMed ID: 37961928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects.
    Flanagan S; Goodman DB; Jandourek A; O'Reilly T; Sandison T
    Clin Pharmacol Drug Dev; 2020 May; 9(4):456-465. PubMed ID: 31793231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
    Gan LM; Lagerström-Fermér M; Ericsson H; Nelander K; Lindstedt EL; Michaëlsson E; Kjaer M; Heijer M; Whatling C; Fuhr R
    Br J Clin Pharmacol; 2019 Apr; 85(4):762-770. PubMed ID: 30618054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis.
    Schilling U; Henrich A; Muehlan C; Krause A; Dingemanse J; Ufer M
    Clin Drug Investig; 2021 Aug; 41(8):711-721. PubMed ID: 34331678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.
    Khindri S; Sabo R; Harris S; Woessner R; Jennings S; Drollmann AF
    BMC Pulm Med; 2011 May; 11():31. PubMed ID: 21615886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
    Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
    Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
    Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
    Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
    Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
    Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
    Newman LM; Kankam M; Nakamura A; Conrad T; Mueller J; O'Donnell J; Osborn BL; Gu K; Saviolakis GA
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0129221. PubMed ID: 34606332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling time-delayed concentration-QT effects with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5a
    Anliker-Ort M; Hsin CH; Krause A; Pfister M; van den Anker J; Dingemanse J; Kaufmann P
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01112. PubMed ID: 37470156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.